share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/10/17 02:12

Moomoo AI 已提取核心信息

180 Life Sciences has entered into a warrant inducement agreement on October 16, 2024, offering holders the opportunity to exercise existing warrants for 954,118 shares at $3.48 per share. If fully exercised, this could generate approximately $3.3 million in gross proceeds before deducting advisory fees.As part of the agreement, the company will issue new unregistered warrants equal to 200% of exercised shares, with an exercise price of $1.50 per share and a five-year term. These new warrants could result in an additional 1,908,236 shares of common stock. The company has engaged A.G.P./Alliance Global Partners as financial advisor, agreeing to pay $232,000 in advisory fees plus up to $65,000 in legal expenses.The company plans to use the net proceeds to advance its recently acquired technology gaming platform commercialization and for working capital purposes. A registration statement for the resale of new warrant shares will be filed by November 15, 2024, with expected effectiveness within 60-90 days.
180 Life Sciences has entered into a warrant inducement agreement on October 16, 2024, offering holders the opportunity to exercise existing warrants for 954,118 shares at $3.48 per share. If fully exercised, this could generate approximately $3.3 million in gross proceeds before deducting advisory fees.As part of the agreement, the company will issue new unregistered warrants equal to 200% of exercised shares, with an exercise price of $1.50 per share and a five-year term. These new warrants could result in an additional 1,908,236 shares of common stock. The company has engaged A.G.P./Alliance Global Partners as financial advisor, agreeing to pay $232,000 in advisory fees plus up to $65,000 in legal expenses.The company plans to use the net proceeds to advance its recently acquired technology gaming platform commercialization and for working capital purposes. A registration statement for the resale of new warrant shares will be filed by November 15, 2024, with expected effectiveness within 60-90 days.
180 Life Sciences在2024年10月16日签署了一项Warrants诱导协议，为持有人提供行使现有Warrants的机会，获得954,118股，每股价格为3.48美元。如果全部行使，预计可以在扣除顾问费用之前产生约330万的毛收益。根据协议，公司将发行新未注册的Warrants，数量等于行使股份的200%，行使价格为每股1.50美元，期限为五年。这些新Warrants可能导致额外的1,908,236股普通股。公司已聘请A.G.P./Alliance Global Partners作为财务顾问，同意支付232,000美元的顾问费用以及最多65,000美元的法律费用。公司计划使用净收益推进其最近获得的科技ARVR游戏平台商业化以及作为营运资金。新的Warrants股份转售的注册声明将在2024年11月15日前提交，预计在60-90天内生效。
180 Life Sciences在2024年10月16日签署了一项Warrants诱导协议，为持有人提供行使现有Warrants的机会，获得954,118股，每股价格为3.48美元。如果全部行使，预计可以在扣除顾问费用之前产生约330万的毛收益。根据协议，公司将发行新未注册的Warrants，数量等于行使股份的200%，行使价格为每股1.50美元，期限为五年。这些新Warrants可能导致额外的1,908,236股普通股。公司已聘请A.G.P./Alliance Global Partners作为财务顾问，同意支付232,000美元的顾问费用以及最多65,000美元的法律费用。公司计划使用净收益推进其最近获得的科技ARVR游戏平台商业化以及作为营运资金。新的Warrants股份转售的注册声明将在2024年11月15日前提交，预计在60-90天内生效。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Lexeo Therapeutics
    LXEO
    -- 4.090
    Polyrizon
    PLRZ
    -- 0.750
    Dominari Holdings
    DOMH
    -- 5.490
    Tonix Pharmaceuticals
    TNXP
    -- 30.5100
    Codexis
    CDXS
    -- 3.070
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点